Jul 12, 2018 - Constellation Pharmaceuticals intends to sell $80 million of its common stock in a U.S. IPO.The firm is developing treatment candidates for a variety of cancers and myelofibrosis diseases.CNST has sho
Jul 12, 2018 - Understanding the root cause for the falling stock price in the last 1.5 years.Improved upside for future revenue growth with more indications.Strong pipeline on Immunotherapy assets.Slightly underval
Jul 06, 2018 - Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.
Jun 02, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Jun 01, 2018 - Tesaro traded into the deep south for the past 52 weeks. Nevertheless, the fundamentals are improving, thus signaling a trading reversal in the making.Revenues from the approved product, niraparib (Ze
May 30, 2018 - Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.
May 23, 2018 -
May 23, 2018 - The stock has been quite volatile, having lost two-thirds of its value since my initial write-up and at one point rising nearly 250% in 2017. I remind readers that cycles of optimism and pessimism pro
May 16, 2018 - The following slide deck was published by Tesaro in conjunction with this event.
May 16, 2018 - Positive CHMP opinion on European approval.Approval in expanded label in USA.A 'bottoming out' of the stock.Comparison of PARPi sales.Maintaining our position in Clovis.